Erasca & Revolution Medicines
2 shared events · Importance 3 · Last updated Aug 10, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Erasca is currently defending against a patent infringement and trade secret misappropriation claim from Revolution Medicines, which alleges Erasca's ERAS-0015 improperly compares to Revolution Medicines' RMC-6236.
Regulatory
Erasca: Erasca is the defendant in multiple class action lawsuits alleging securities fraud due to misleading statements about its drug candidate ERAS-0015, patent infringement claims, and a patient death during clinical trials. This has led to a significant drop in its stock price and market capitalization.
Revolution Medicines: Revolution Medicines is the company that accused Erasca of patent infringement and trade secret misappropriation related to Erasca's ERAS-0015, claiming improper comparisons to its own drug candidate RMC-6236. This action has negatively impacted Erasca.
May 19, 2026 · 323 articles
Regulatory
Erasca: Erasca is the defendant in the securities class action, accused of misleading investors about ERAS-0015. Its stock collapsed over 45% following disclosures of patent disputes and a patient death, erasing billions in market value.
Revolution Medicines: Revolution Medicines is the competitor whose patent and trade secret claims against Erasca triggered the stock drop. The allegations could strengthen its competitive position in the RAS-targeting space.
Jun 11, 2026 · 193 articles
87
Revolution Medicines sent letter alleging infringement ErascaErasca Securities Fraud...
80
Erasca misrepresented preclinical data Revolution MedicinesErasca Securities Fraud...
ERGEN INTELLIGENCE
Explore this relationship live
Track how Erasca and Revolution Medicines interact across events, view sentiment trends, and discover connected entities.
Open Dashboard